Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F17%3A10410626" target="_blank" >RIV/00179906:_____/17:10410626 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/17:10362335 RIV/00064190:_____/17:N0000160
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Kv35kPSXsN" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Kv35kPSXsN</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1701488" target="_blank" >10.1056/NEJMoa1701488</a>
Alternative languages
Result language
angličtina
Original language name
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Original language description
BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
The New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
376
Issue of the periodical within the volume
16
Country of publishing house
US - UNITED STATES
Number of pages
13
Pages from-to
1527-1539
UT code for WoS article
000399534600007
EID of the result in the Scopus database
2-s2.0-85018314556